Results 151 to 160 of about 16,400 (171)

The incidence of spontaneous HBsAg loss in patients with different baseline HBsAg levels: a systematic review and meta-analysis

Hepatology International
Shulan Sui, Hanqiang Li, Ruirui You, Jiqin Wu, Jibing Xin, Tingting Zhao, Yan Miao, Yanfei Ren, Yueting Qu, Xiangyue Wang, Xu Liu, Wenting Huang, Ting Li, Jun Ying, Wenhong Zhang, Xi Liu, Qiran Zhang   +16 more
openaire   +1 more source

Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAG

Journal of Hepatology, 1997
Marie-Anne Loriot, Patrick Marcellin, Nathalie Boyer   +2 more
exaly  

413 AGE AND THE INACTIVE HBsAg CARRIER STATE ARE PREDICTIVE OF HBsAg LOSS IN A “REAL-LIFE” COHORT OF PATIENTS WITH CHRONIC HBV INFECTION

Journal of Hepatology, 2013
F. Habersetzer, R. Moenne-Loccoz, N. Meyer, E. Schvoerer, P. Simo-Noumbissie, S. Dritsas, F. Stoll-Keller, S. Fafi-Kremer, T.F. Baumert, M. Doffo el   +9 more
openaire   +1 more source

Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study

Journal of Infectious Diseases, 2018
I-Cheng Lee, Sien-Sing Yang, Chien-Wei Su   +2 more
exaly  

Peginterferon α-2b Enhances HBsAg Loss in NA-Suppressed Low-HBsAg Chronic Hepatitis B Patients: Everest Study in China.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Patients with chronic hepatitis B (CHB) with low hepatitis B surface antigen (HBsAg) levels and suppressed hepatitis B virus (HBV) DNA on nucleos(t)ide analogues (NAs) may achieve functional cure with peginterferon α (PegIFNα)-based therapy. This real-world multicenter study (Everest Project) in China aimed to evaluate the effectiveness and safety of ...
Chan, Xie, Bingliang, Lin, Zhishuo, Mo, Lei, Fu, Xinyue, Chen, Jiahong, Yang, Guojun, Li, Jiabin, Li, Yilan, Zeng, Guozhong, Gong, Wenhua, Zhang, Hong, Tang, Ying, Guo, Jia, Wei, Jiaji, Jiang, Xiaoping, Wu, Riying, Lv, Minghua, Lin, Zujiang, Yu, Jia, Shang, Yujuan, Guan, Junyi, Li, Lingyi, Zhang, Qian, Guo, Qing, Ye, Qing, Mao, Yi, Li, Xiulan, Xue, Jiawei, Geng, Xiaorong, Mao, Jianqi, Lian, Xiaobo, Lu, Guoxin, Hu, Honglian, Bai, Dachuan, Cai, Youde, Liu, Liting, Zhang, Qianguo, Mao, Jia, Li, Hui, Chen, Jiabao, Chang, Qiang, Li, Dongying, Xie, Hong, Deng, Qihuan, Xu, Liang, Peng, Xizhong, Yang, Hui, Zhuang, Zhiliang, Gao   +48 more
openaire   +1 more source

Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment

Clinical Immunology, 2019
Muye Xia, Guichan Liao, Rong Fan
exaly  

The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment

Journal of Hepatology, 2014
Chien-Hung Chen, , Chao-Hung Hung
exaly  

PS-077-Lenvervimab, a monoclonal antibody against HBsAg, can induce sustained HBsAg loss in a chronic hepatitis B mouse model

Journal of Hepatology, 2019
Jung-Hwan Kim, Hyunjin Kim, Tae-Hee Kim, Woohyun Kim, Jaesung Jung, Ara Lee   +5 more
openaire   +1 more source

HBsAg loss during treatment with nucleo(s)tide analogues is preceded by changes of the composition of the hepatitis B virus surface antigen (HBsAg)

Journal of Hepatology, 2017
M. Grossmann, T. Schott, C. Felkel, S. Boehm, D. Glebe, T. Berg, F. Van Bömmel   +6 more
openaire   +1 more source

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate

Alimentary Pharmacology & Therapeutics
Wen‐Juei Jeng, Yun‐Fan Liaw
openaire   +2 more sources